Do you see patients with
Learn about our research studies of an investigational agent targeting myelofibrosis and related diseases.
Patients who are diagnosed with myelofibrosis will experience constitutional symptoms, splenomegaly, an increased risk of transformation to acute myeloid leukemia (AML), and a shortened life expectancy. As an acquired clonal Philadelphia chromosome negative myeloproliferative neoplasm (MPN), myelofibrosis can present in a number of ways. Patients may be diagnosed with primary myelofibrosis or secondary myelofibrosis following progression of polycythemia vera (PV) to post-PV myelofibrosis, or essential thrombocythemia (ET) to post-ET myelofibrosis. Other than hematopoietic stem cell transplantation (HSCT), current therapies are unable to control all of the clinical manifestations of myelofibrosis. Our research is focusing on potential new treatment options, including combination strategies with ruxolitinib as the backbone treatment.
We are conducting several research studies to evaluate an investigational agent called navitoclax in patients with myelofibrosis. The primary objective of this program is to evaluate the effect of navitoclax (in most cases, in combination with ruxolitinib) on reducing spleen volume in patients with myelofibrosis. We are also conducting a multi-cohort research study evaluating navitoclax in patients with various MPN disease types. Patients in all of these studies may continue on the study treatment as long as they are receiving benefit. We need help from the local medical community to help us identify qualified study participants around the world.
Navitoclax is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.
ENROLLMENT HAS BEEN CLOSED
The research studies are being conducted at research centers across the globe.
Please note, not all sites may be listed on the map. For a full list of all planned and opened sites, you may review on ClinicalTrials.gov and the links below:
If you would like to learn more about these AbbVie research studies and speak to a Principal Investigator to find out if your patients may be eligible, please complete the form below and you will be contacted by a member of the research team. Thank you for your interest.